Articles tagged "Graft survival"

2022 American Transplant Congress
Variability In Plasma Donor-derived Cell-free DNA Levels With CLAD More Than 5-years After Lung Transplantation: Pilot Data
D. Levine¹, D. Ross²
¹Department of Medicine, University of Texas, San Antonio, San Antonio, TX, ²Natera, Inc., Ausin, TX
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been clinically validated for detection of acute rejection (AR) in lung transplant (LT) although studies have typically focused on…
2022 American Transplant Congress
Association of Trugraf GEP with Clinical and Histological Outcomes in a Multicenter Cohort (TOGETHER Study)
R. Heilman¹, W. Park², M. Mai³, B. Smith², R. First⁴, J. Fleming⁴, P. West-Thielke⁴, J. Holman⁴, M. Stegall²
¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Jacksonville, FL, ⁴Transplant Genomics, Framingham, MA
*Purpose: The purpose of this study was to validate the association of TruGraf GEP with clinical endpoints in a real-world cohort.*Methods: This was a multicenter…
2022 American Transplant Congress
Variability of Serum Klotho and FGF-23 Levels During the First Two Years After Kidney Transplantation
T. Vazquez-Sanchez¹, M. Sanchez-Niño², P. Ruiz-Esteban¹, V. López¹, J. Delgado¹, A. Ortiz³, D. Hernández¹
¹Nephrology Department, Regional University Hospital (IBIMA), REDinREN (RD16/0009/0006), Malaga (España), Malaga, Spain, ²Nephrology Department, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Universidad Autónoma de Madrid. REDINREN, Madrid, Spain, ³Nephrology Department, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Universidad Autónoma de Madrid. REDINREN, Madrid, Spain, Madrid, Spain
*Purpose: Klotho is a protein produced in renal tubular cells with nephroprotective actions which acts as a co-receptor for phosphaturic factor FGF-23. The natural history…
2021 American Transplant Congress
Incorporation of Donor Liver Macrovesicular Steatosis Into Srtr Risk Adjustment Models for Deceased Donor Yield and Post-Transplant Outcome
A. Kwong¹, C. Wang², A. Wey³, N. Salkowski³, J. Snyder⁴, J. Wetmore², A. Israni², J. Lake⁴, P. Stock⁵, W. Kim¹
¹Stanford University, Redwood City, CA, ²Medicine, Hennepin Healthcare, Minneapolis, MN, ³Scientific Registry of Transplant Recipients, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵University of California, San Francisco, San Francisco, CA
*Purpose: The SRTR had not traditionally included biopsy results in post-transplant risk adjustment, yet biopsy results may influence outcomes and thus decisions regarding organ acceptance.…
2021 American Transplant Congress
Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials
C. Goerlich¹, B. Griffith¹, A. Singh¹, T. Zhang¹, I. Tatarov¹, B. Lewis¹, F. Sentz¹, A. Hershfeld¹, P. Odonkor¹, B. Williams¹, E. Strauss¹, A. Tabatabai², A. Bhutta³, D. Ayares⁴, D. Kaczorowski¹, M. Mohiuddin¹
¹Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ³Pediatrics, Pediatric Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Revivicor, Inc., Blacksburg, VA
*Purpose: Cardiac xenotransplantation has been proposed to bridge the gap in organ shortage for those in end-stage heart failure without the opportunity to receive a…
2021 American Transplant Congress
Survival Outcomes in Kidney Transplant Recipients Aged 18-60 Years by CMV Discordance Status: A Multivariable Analysis
A. Dinesh¹, T. Shaker¹, S. Jackson², S. Riad³, T. L. Pruett¹
¹Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, ²Biostatistics, Analytics Consulting Services- Solid Organ Transplant, M Health Fairview, Minneapolis, MN, ³Department of Medicine, University of Minnesota, Minneapolis, MN
*Purpose: Despite advances in CMV therapeutics, CMV infection can pose significant comorbidity after transplantation. We sought to examine the impact of high-risk CMV discordance in…
2021 American Transplant Congress
Desensitization with Plasmapheresis and IV Immunoglobulin is Safe and Effective in Pra Positive Kidney Transplant Recipient Candidates in Covid-19 Pandemic Period
B. Sayin¹, A. Akdur², E. Karakaya², U. Musabak³, T. Colak¹, M. Haberal²
¹Department of Nephrology, Baskent University, Ankara, Turkey, ²Division of Transplantation, Department of General Surgery, Baskent University, Ankara, Turkey, ³Department of Immunology, Baskent University, Ankara, Turkey
*Purpose: High panel reactive antibody (PRA) levels may limit living-donor kidney transplantation (LDKT) according to increased risk of antibody mediated rejection. Desensitization may provide better…
2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
W. Fitzsimmons¹, J. Erdman², J. Wolfram³, D. Nimke², R. Croy², X. Wang², T. Weaver⁴, D. Schladt⁴
¹University of Illinois at Chicago, College of Pharmacy, Vernon Hills, IL, ²Astellas Pharma, Inc, Northbrook, IL, ³Astellas Pharma Europe BV, Leiden, Netherlands, ⁴Chronic Disease Research Group, Minneapolis, MN
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…
2021 American Transplant Congress
Findings from the Bareto Study: Associations Between Chronic Vascular Changes and 10-year Transplant Graft Outcomes
L. Kamal¹, D. Stewart², J. Foutz², H. McGehee², P. Saravanane¹, S. Yu¹, R. Yusfi¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: As part of a broader study on Biopsy, Anatomy, and Resistance Effects on Transplant Outcomes (BARETO), we aim to characterize the poorly understood relationship…
2021 American Transplant Congress
Immunologic Endotypes of Ischemia-reperfusion Injury in Human Liver Transplantation
R. A. Sosa, A. Q. Terry, F. M. Kaldas, B. V. Naini, T. Ito, R. W. Busuttil, D. W. Gjertson, J. W. Kupiec-Weglinski, E. F. Reed
UCLA, Los Angeles, CA
*Purpose: Ischemia-reperfusion injury (IRI) is a major risk factor for allograft rejection in orthotopic liver transplantation (OLT), involving complex interactions between innate and adaptive immune…